락토바실러스 카세이 시로타

The Effect of Probiotics on the Management of Pain and Inflammation in Osteoarthritis: A Systematic Review and Meta-Analysis of Clinical Studies.

1. Nutrients. 2024 Jul 12;16(14):2243. doi: 10.3390/nu16142243. The Effect of Probiotics on the Management of Pain and Inflammation in Osteoarthritis: A Systematic Review and Meta-Analysis of Clinical Studies. Moyseos M(1)(2), Michael J(1), Ferreira N(3), Sophocleous A(1). Author information: (1

Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials.

2. Clin Nutr. 2022 Dec;41(12):2759-2777. doi: 10.1016/j.clnu.2022.10.015. Epub 2022 Oct 27. Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. van der Schoot A(1), Helander C(2), Whelan K(3), Dimidi E(4). Author in

The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials.

3. Am J Clin Nutr. 2014 Oct;100(4):1075-84. doi: 10.3945/ajcn.114.089151. Epub 2014 Aug 6. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Dimidi E(1), Christodoulides S(1), Fragkos KC(1), Scott SM(1), Whelan K

[Probiotics as therapeutic agents in irritable bowel syndrome].

4. Z Gastroenterol. 2005 May;43(5):467-71. doi: 10.1055/s-2004-813934. [Probiotics as therapeutic agents in irritable bowel syndrome]. [Article in German] Krammer HJ(1), Schlieger F, Harder H, Franke A, Singer MV. Author information: (1)II. Medizinische Universitätsklinik (Gastroenterologie, Hep

A randomized controlled trial of probiotics to reduce the severity of oral mucositis in patients with oropharyngeal carcinoma undergoing concurrent chemoradiotherapy.

5. J Cancer Res Ther. 2026 Jan 1;22(1):115-119. doi: 10.4103/jcrt.jcrt_1070_25. Epub 2026 Mar 30. A randomized controlled trial of probiotics to reduce the severity of oral mucositis in patients with oropharyngeal carcinoma undergoing concurrent chemoradiotherapy. Sojitra S(1), Soni TP(1), Patn

Lactobacillus casei Shirota probiotic drinks reduce antibiotic associated diarrhoea in patients with spinal cord injuries who regularly consume proton pump inhibitors: a subgroup analysis of the ECLISP multicentre RCT.

6. Spinal Cord. 2024 May;62(5):255-263. doi: 10.1038/s41393-024-00983-w. Epub 2024 Mar 22. Lactobacillus casei Shirota probiotic drinks reduce antibiotic associated diarrhoea in patients with spinal cord injuries who regularly consume proton pump inhibitors: a subgroup analysis of the ECLISP mul

Effects of Probiotics on Anxiety, Stress, Mood and Fitness of Badminton Players.

7. Nutrients. 2021 May 24;13(6):1783. doi: 10.3390/nu13061783. Effects of Probiotics on Anxiety, Stress, Mood and Fitness of Badminton Players. Salleh RM(1), Kuan G(2)(3), Aziz MNA(1), Rahim MRA(1), Rahayu T(4), Sulaiman S(4), Kusuma DWY(4), Adikari AMGCP(1)(5), Razam MSM(1), Radhakrishnan AK(6),

Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review.

8. Travel Med Infect Dis. 2015 Mar-Apr;13(2):128-34. doi: 10.1016/j.tmaid.2015.03.001. Epub 2015 Mar 10. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Xie C(1), Li J(1), Wang K(2), Li Q(1), Chen D(3). Author information: (1)Department o

Systematic review of randomised controlled trials: probiotics for functional constipation.

9. World J Gastroenterol. 2010 Jan 7;16(1):69-75. doi: 10.3748/wjg.v16.i1.69. Systematic review of randomised controlled trials: probiotics for functional constipation. Chmielewska A(1), Szajewska H. Author information: (1)Department of Paediatrics, The Medical University of Warsaw, 01-184 Warsa

Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable bowel syndrome: a systematic review and network meta-analysis.

1. Eur J Gastroenterol Hepatol. 2026 Jan 1;38(1):27-35. doi: 10.1097/MEG.0000000000003062. Epub 2025 Aug 25. Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable bowel syndrome: a systematic review and network meta-analysis. Rokkas T(1)(2), Ekmektzoglou K(1)(2), Tsanou E(3), Bricca L(4), Menni AE(5), Golfakis P(6), Kotzampassi K(5). Author information: (1)Gastroenterology Clinic, Henry Dunant Hospital, Athens, Greece. (2)Medical School, European University of Cyprus, Nicosia, Cyprus. (3)Department of Biotechnology of the Agricultural University of Athens, Athens, Greece. (4)Section of Hyigiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy. (5)Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki. (6)Hepatogastroenterology Unit, Second Department of Internal Medicine - Propaedeutic, Medical School, National and Kapodistrian University of Athens, ''Attikon" University General Hospital, Athens, Greece. BACKGROUND: The use of probiotics as a treatment for irritable bowel syndrome (IBS) is gaining attention, with recent studies indicating that certain probiotics or combinations may have mental health benefits for patients with IBS. AIMS: To systematically review and meta-analyze, using network meta-analysis (NWM), the comparative effectiveness and safety of probiotics with psychotropic potential on quality of life, depression, and anxiety in patients with IBS. METHODS: Relevant randomized controlled trials (RCTs) were analyzed, using a Bayesian NWM, to compare the performance of probiotics with mental health benefits in IBS treatment. Treatment effectiveness was assessed using surfaces under cumulative ranking (SUCRA) values. RESULTS: The analysis included 3154 participants assigned to nine different treatments: Bifidobacterium longum, Saccharomyces, Clostridium butyricum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus casei strain Shirota, Lactobacillus plantarum, probiotic combinations, and placebo. B. longum and probiotic combinations were found to be significantly more effective than placebo. In terms of improving quality of life (QoL), B. longum was the most effective (SUCRA = 89.7%), while L. plantarum was the least effective (SUCRA = 14.9%). For alleviating depression and anxiety, the combination of probiotics (SUCRA = 95.6%) and L. acidophilus (SUCRA = 74.2%) showed the best results, respectively. CONCLUSION: Some probiotics or combinations may offer benefits for patients with IBS in improving QoL, depression, and anxiety; however, as this is a developing field, additional research is necessary to fully understand the effectiveness, underlying mechanisms, and specific strains that may be advantageous. More high-quality RCTs are needed to substantiate these therapeutic possibilities. Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MEG.0000000000003062 PMID: 40929652 [Indexed for MEDLINE]

Effects of dietary supplements on patients with osteoarthritis: A systematic review and network meta-analysis.

2. J Integr Med. 2025 Jul;23(4):357-369. doi: 10.1016/j.joim.2025.04.008. Epub 2025 May 3. Effects of dietary supplements on patients with osteoarthritis: A systematic review and network meta-analysis. Chen CS(1), Wen L(1), Yang F(2), Deng YC(1), Ji JH(1), Chen RJ(3), Chen Z(1), Chen G(4), Gu JY(5). Author information: (1)Department of Orthopedics and Trauma Surgery, Affiliated Hospital of Yunnan University, Kunming 650032, Yunnan Province, China. (2)Department of Orthopedics, Nanchong Central Hospital, Nanchong 637000, Sichuan Province, China. (3)Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou 730030, Gansu Province, China. (4)Department of Orthopedics and Trauma Surgery, Affiliated Hospital of Yunnan University, Kunming 650032, Yunnan Province, China. Electronic address: Chenge007.good@163.com. (5)Clinical Laboratory of Affiliated Hospital of Yunnan University, Kunming 650032, Yunnan Province, China. Electronic address: janegu@ynu.edu.cn. BACKGROUND: A growing body of research is exploring the role of antioxidant and anti-inflammatory dietary supplements in the treatment of osteoarthritis, highlighting an increasing emphasis on non-pharmacological interventions. Although more patients are turning to supplements to manage osteoarthritis, their actual effectiveness remains uncertain. OBJECTIVE: This study aims to provide a comprehensive evaluation of the available evidence concerning the efficacy of various dietary supplements in osteoarthritis treatment. SEARCH STRATEGY: We searched PubMed, Embase, Cochrane Library and Web of Science for studies on the use of various dietary supplements in the treatment of osteoarthritis from the creation of each database until Jan 20, 2025. INCLUSION CRITERIA: (1) Research object: osteoarthritis. (2) Intervention measures: patients in the treatment group received dietary supplements, while the control group received placebos. (3) Research type: randomized controlled trials (RCTs). DATA EXTRACTION AND ANALYSIS: Two researchers independently examined the literature and retrieved data based on predefined criteria. The information gathered included the first author, year of publication, sample size, participant demographics, length of the follow-up period, intervention and control measures, and inclusion indications. RCTs comparing dietary supplements to placebo with the pain and function subscales of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) among patients with osteoarthritis were included. The optimal dietary supplement was identified based on the total ranking by summing the surface under the cumulative ranking curve (SUCRA) of these two scores. Furthermore, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to confirm the quality of the evidence. RESULTS: Overall, 23 studies covering 21 dietary supplements and involving 2455 participants met the inclusion criteria. In the WOMAC pain score, the SUCRA of passion fruit peel extract was 91% (mean difference [MD]: -9.2; 95% confidence interval [CI]: [-16.0, -2.3]), followed by methylsulfonylmethane (89%), undenatured type II collagen (87%), collagen (84%), and Lanconone (82%). The SUCRA (99%) of passion fruit peel extract (MD: -41.0; 95% CI: [-66.0, -16.0]) ranked first in terms of the WOMAC function score, followed by Lanconone (95%), collagen (86%), ParActin (84%), and Lactobacillus casei strain Shirota (83%). The top three total rankings are passion fruit peel extract (95.0%), Lanconone (88.5%), and collagen (85.0%). However, the GRADE revealed low evidence quality. CONCLUSION: Passion fruit peel extract was the best supplement for improving WOMAC pain and function scores in patients with osteoarthritis, followed by Lanconone and collagen. However, further large-scale, well designed RCTs are required to substantiate these promising findings. Please cite this article as: Chen CS, Wen L, Yang F, Deng YC, Ji JH, Chen RJ, Chen Z, Chen G, Gu JY. Effects of dietary supplements on patients with osteoarthritis: A systematic review and network meta-analysis. J Integr Med. 2025; 23(4): 357-369. Copyright © 2025 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. All rights reserved. DOI: 10.1016/j.joim.2025.04.008 PMID: 40425393 [Indexed for MEDLINE]

Two-Month Consumption of Orange Juice Enriched with Vitamin D3 and Probiotics Decreases Body Weight, Insulin Resistance, Blood Lipids, and Arterial Blood Pressure in High-Cardiometabolic-Risk Patients on a Westernized Type Diet: Results from a Randomized Clinical Trial.

3. Nutrients. 2024 Apr 28;16(9):1331. doi: 10.3390/nu16091331. Two-Month Consumption of Orange Juice Enriched with Vitamin D3 and Probiotics Decreases Body Weight, Insulin Resistance, Blood Lipids, and Arterial Blood Pressure in High-Cardiometabolic-Risk Patients on a Westernized Type Diet: Results from a Randomized Clinical Trial. Papakonstantinou E(1), Zacharodimos N(1), Georgiopoulos G(2), Athanasaki C(1), Bothou DL(1), Tsitsou S(1), Lympaki F(1), Vitsou-Anastasiou S(3)(4), Papadopoulou OS(3), Delialis D(2), Alexopoulos EC(5), Petsiou E(6), Keramida K(7), Doulgeraki AI(8), Patsopoulou IM(3), Nychas GE(4)(9), Tassou CC(3). Author information: (1)Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, School of Food and Nutritional Sciences, Agricultural University of Athens, 11855 Athens, Greece. (2)Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 80 Vasilissis Sophias Ave, 11528 Athens, Greece. (3)Institute of Technology of Agricultural Products, Hellenic Agricultural Organization "DIMITRA", 1, S. Venizelou, Lykovrissi, 14123 Attiki, Greece. (4)Laboratory of Microbiology and Biotechnology of Foods, Department of Food Science and Human Nutrition, School of Food and Nutritional Sciences, Agricultural University of Athens, 75 Iera Odos, 11855 Athens, Greece. (5)Ergomneia Medical PCC, Ellispontou 11, 15669 Papagos, Greece. (6)Henry Dunant Hospital, 107 Mesogeion Ave, 11526 Athens, Greece. (7)Cardiology Department, General Anticancer Oncological Hospital Agios Savvas, 171 Alexandras Ave, 11522 Athens, Greece. (8)Laboratory of Food Microbiology and Hygiene, Department of Food Science and Technology, School of Agriculture, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. (9)Shandong Agricultural University, Tai'an 271002, China. This study examined the effects of orange juice (OJ) supplemented with vitamin D3 (2000 IU) and probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG, 108 cfu/mL) on cardiometabolic risk factors in overweight and obese adults following a Westernized-type diet. Fifty-three high-risk individuals were randomly assigned to one of two groups. Over 8 weeks, one group consumed a vitamin D3 and probiotic-enriched OJ and the other regular OJ (control). Diets remained unchanged and were documented through food diaries. Measures of metabolic and inflammatory markers and blood pressure were measured at the start and end of the study. Post-intervention, the enriched OJ group showed the following significant metabolic improvements (without changes in triglycerides, inflammation, or central blood pressure): reduced fasting insulin, peripheral blood pressure, body weight (-1.4 kg 95% CI: -2.4, -0.4), energy (-270 kcal 95% CI: -553.2, -13.7), macronutrient (dietary fat -238 kcal 95% CI: -11.9, -1.0; carbohydrates -155 kcal 95% CI: -282.4, -27.3; sugars -16.1 g 95% CI: -11.9, -1.0) intake, and better lipid profiles (total cholesterol -10.3 mg/dL 95% CI: -21.4, 0.9; LDL-C -7 mg/dL 95% CI: -13.5, -0.5). The enriched OJ led to weight loss, less energy/macronutrient consumption, improved lipid profiles, and increased insulin sensitivity after 8 weeks in those following a Westernized diet, thus indicating potential benefits for cardiometabolic risk. This study was a part of FunJuice-T2EDK-01922, which was funded by the EU Regional Development Fund and Greek National Resources. DOI: 10.3390/nu16091331 PMCID: PMC11085203 PMID: 38732578 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest. The funders had no role in the study design; collection, analyses, or interpretation of data; writing of the manuscript; or decision to publish the results.

Effects of Lacticaseibacillus paracasei Strain Shirota on Daytime Performance in Healthy Office Workers: A Double-Blind, Randomized, Crossover, Placebo-Controlled Trial.

4. Nutrients. 2023 Dec 15;15(24):5119. doi: 10.3390/nu15245119. Effects of Lacticaseibacillus paracasei Strain Shirota on Daytime Performance in Healthy Office Workers: A Double-Blind, Randomized, Crossover, Placebo-Controlled Trial. Kikuchi-Hayakawa H(1), Ishikawa H(1), Suda K(1)(2), Gondo Y(1), Hirasawa G(1), Nakamura H(1), Takada M(1), Kawai M(1), Matsuda K(1). Author information: (1)Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan. (2)Yakult Honsha European Research Center for Microbiology VOF, Technologiepark 94 bus 3, 9052 Ghent, Belgium. Lacticaseibacillus paracasei strain Shirota (LcS) modulates psychological homeostasis via the gut-brain axis. To explore the possible efficacy of LcS for improving daytime performance, we conducted a double-blind, randomized, crossover, placebo-controlled study of 12 healthy office workers with sleep complaints. The participants received fermented milk containing viable LcS (daily intake of 1 × 1011 colony-forming units) and non-fermented placebo milk, each for a 4-week period. In the last week of each period, the participants underwent assessments of their subjective mood and measurements of physiological state indicators via an electroencephalogram (EEG) and heart rate variability in the morning and afternoon. The attention score in the afternoon as assessed by the visual analog scale was higher in the LcS intake period than in the placebo intake period (p = 0.041). Theta power on EEG measured at rest or during an auditory oddball task in the afternoon was significantly lower in the LcS period than in the placebo period (p = 0.025 and 0.009, respectively). The change rate of theta power was associated with the change in attention score. Treatment-associated changes were also observed in heart rate and the sympathetic nerve activity index. These results indicate that LcS has possible efficacy for improving daytime performance, supported by observations of the related physiological state indicators. DOI: 10.3390/nu15245119 PMCID: PMC10745872 PMID: 38140378 [Indexed for MEDLINE] Conflict of interest statement: H.K.-H., H.I., Y.G., G.H., M.T., M.K. and K.M. are employees of the Yakult Central Institute, Yakult Honsha Co., Ltd. K.S. and H.N. were the employees at the time of this work. H.K.-H., H.I. and K.M. are inventors of a pending patent related to this work (patent applicant: Yakult Honsha Co., Ltd., Tokyo, Japan; application number: Japanese Patent Application No. 2023-152247; status of application: application).

Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson's disease.

5. Food Funct. 2023 Jul 31;14(15):6828-6839. doi: 10.1039/d3fo00728f. Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson's disease. Yang X(1), He X(1), Xu S(1), Zhang Y(1), Mo C(1), Lai Y(1), Song Y(2), Yan Z(3), Ai P(1), Qian Y(1), Xiao Q(1). Author information: (1)Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China. qyw12344@rjh.com.cn. (2)Department of Biostatistics, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. (3)Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, PR China. Parkinson's disease (PD) is a common neurodegenerative disease characterized by motor issues and a range of non-motor symptoms. Microbial therapy may be a useful approach for the treatment of PD. However, comprehensive analyses of the impact of probiotic supplementation on motor and non-motor symptoms are still lacking and the mechanisms whereby the treatment works remain unclear. This study investigated Lacticaseibacillus paracasei strain Shirota (LcS) supplementation on clinical responses, gut microbiota and faecal metabolites in PD patients. Patients (n = 128) were randomised to receive either probiotics (LcS-fermented milk, containing 1 × 1010 living LcS cells) or placebo for 12 weeks. All participants were examined and the basic clinical features were recorded using questionnaires. Fecal and blood samples were collected at the baseline and after 12 weeks for further omics analysis. We found that LcS intervention significantly alleviated patients' constipation-related symptoms and non-motor symptoms. We found no significant shifts in the composition of gut microbiota or faecal metabolites. Several taxa were differentially abundant between the groups, especially with regard to LcS intake, which increased the abundance of the genus Lacticaseibacillus in the probiotic group compared with those at the baseline and in the placebo group. The faecal concentration of L-tyrosine was significantly decreased and the plasma concentration of L-tyrosine was increased in the probiotic group compared with the placebo group. Our study demonstrated that although supplementation with LcS did not induce major changes in the global gut microbiome, the probiotic had favorable effects in managing constipation and other non-motor symptoms in PD patients. This study was registered at the Chinese Clinical Trial Registry: ChiCTR1800016795. DOI: 10.1039/d3fo00728f PMID: 37470081 [Indexed for MEDLINE]

Agave fructans enhance the effects of fermented milk products on obesity biomarkers: a randomised trial.

6. Benef Microbes. 2023 Apr 18;14(2):153-164. doi: 10.3920/BM2022.0078. Epub 2023 Mar 1. Agave fructans enhance the effects of fermented milk products on obesity biomarkers: a randomised trial. Vega-Cárdenas M(1), Martínez-Gutierrez F(1)(2), Lara-Ramírez EE(3), Reynaga-Hernandez E(2), Yañez-Estrada L(4), Ratering S(5), Schnell S(5), Godínez-Hernández CI(6), Vargas-Morales JM(2), Portales-Pérez DP(1)(2). Author information: (1)Research Centre for Health Sciences and Biomedicine, Autonomous University of San Luis Potosí (UASLP), Av. Sierra Leona 550, Lomas de San Luis 78210, San Luis Potosí, SLP, Mexico. (2)Faculty of Chemical Sciences, UASLP, Av. Dr. Manuel Nava 6, Zona Universitaria 78210, San Luis Potosí, SLP, Mexico. (3)Zacatecas Biomedical Research Unit, Mexican Social Security Institute (IMSS), Alameda Trinidad García de La Cadena 438, Zacatecas Centro 98000 Zacatecas, Zac, Mexico. (4)Faculty of Medicine, UASLP, Av. Dr. Manuel Nava 6, Zona Universitaria 78210, San Luis Potosí, SLP, Mexico. (5)Institute of Applied Microbiology, Justus Liebig University, Schubertstr. 81 35392, Giessen, Germany. (6)Desert Zones Research Institute, UASLP, De Altair 200, Col del Llano, 78377, San Luis Potosí, SLP, Mexico. Dysbiosis has been implicated in childhood obesity. Oral intake of fermented milk containing Lacticaseibacillus casei strain Shirota preserves gut microbiota (GM) diversity in children and adults. This study was a double-blind trial involving 37 overweight or obese children aged 6-10 years. Children were followed over a 6-week intervention period in which they received different fermented milk products containing L. casei Shirota: 10 in the first group received just L. casei Shirota; 13 received L. casei Shirota with 3 g/day of inulin (L. casei+inulin); and 14 received L. casei Shirota with 3 g/day of fructans from Agave salmiana (L. casei+fructans). Principal component analysis showed the relationship between microbial abundance, GM metabolites, and other obesity-related markers. Supplementation with probiotics and synbiotics improved the HDL-cholesterol levels of overweight and obese children, although no changes in body composition were detected. We observed an increase in butyrate or propionate concentrations in the L. casei+fructans group compared to the end of the intervention (P<0.03). A diminished level of ANGPTL4 within the L. casei+fructans group (P=0.04) was also found, but no differences when lipopolysaccharide-binding protein was evaluated. The FFAR2+ cell frequency decreased between baseline and at the end of 6-week intervention in L. casei+inulin (P=0.02) and L. casei+fructans groups (P=0.04). In contrast, the percentage of CD14+FFAR3+ frequency increased in the same groups (P=0.04). The L. casei Shirota with inulin or fructans modulates GM, which improves the lipid profile and changes at a molecular level, such as expression of FFAR3 and FFAR2, ANGPTL4, propionate, and butyrate. It, therefore, could be considered an interesting therapeutic possibility for treating childhood overweight and obesity. The study was registered at ClinicalTrials.gov (ID: NCT05423015). DOI: 10.3920/BM2022.0078 PMID: 36856122 [Indexed for MEDLINE]

Effects of Fermented Milk Containing Lacticaseibacillus paracasei Strain Shirota on Constipation in Patients with Depression: A Randomized, Double-Blind, Placebo-Controlled Trial.

7. Nutrients. 2021 Jun 29;13(7):2238. doi: 10.3390/nu13072238. Effects of Fermented Milk Containing Lacticaseibacillus paracasei Strain Shirota on Constipation in Patients with Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. Zhang X(1), Chen S(1), Zhang M(2), Ren F(1), Ren Y(3), Li Y(1), Liu N(1), Zhang Y(4), Zhang Q(1), Wang R(1). Author information: (1)Department of Nutrition and Health, China Agricultural University, Beijing 100091, China. (2)School of Food and Chemical Engineering, Beijing Technology and Business University, Beijing 100048, China. (3)Key Laboratory of Functional Dairy, Co-Constructed by Ministry of Education and Beijing Government China Agricultural University, Beijing 100083, China. (4)Hebei Engineering Research Center of Animal Product, Sanhe 065200, China. Probiotics have been shown to benefit patients with constipation and depression, but whether they specifically alleviate constipation in patients with depression remains unclear. The aim of this study was to investigate the effect of Lacticaseibacillus paracasei strain Shirota (LcS), formerly Lactobacillus casei strain Shirota, on constipation in patients with depression with specific etiology and gut microbiota and on depressive regimens. Eighty-two patients with constipation were recruited. The subjects consumed 100 mL of a LcS beverage (108 CFU/mL) or placebo every day for 9 weeks. After ingesting beverages for this period, we observed no significant differences in the total patient constipation-symptom (PAC-SYM) scores in the LcS group when compared with the placebo group. However, symptoms/scores in item 7 (rectal tearing or bleeding after a bowel movement) and items 8-12 (stool symptom subscale) were more alleviated in the LcS group than in the placebo group. The Beck Depression Index (BDI) and Hamilton Depression Rating Scale (HAMD) scores were all significantly decreased, and the degree of depression was significantly improved in both the placebo and LcS groups (p < 0.05), but there was no significant difference between the groups. The LcS intervention increased the beneficial Adlercreutzia, Megasphaera and Veillonella levels and decreased the bacterial levels related to mental illness, such as Rikenellaceae_RC9_gut_group, Sutterella and Oscillibacter. Additionally, the interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) levels were significantly decreased in both the placebo and LcS groups (p < 0.05). In particular, the IL-6 levels were significantly lower in the LcS group than the placebo group after the ingestion period (p < 0.05). In conclusion, the daily consumption of LcS for 9 weeks appeared to relieve constipation and improve the potentially depressive symptoms in patients with depression and significantly decrease the IL-6 levels. In addition, the LcS supplementation also appeared to regulate the intestinal microbiota related to mental illness. DOI: 10.3390/nu13072238 PMCID: PMC8308326 PMID: 34209804 [Indexed for MEDLINE] Conflict of interest statement: The authors declare they have no conflict of interest.

Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study.

8. Nutrients. 2021 Feb 8;13(2):558. doi: 10.3390/nu13020558. Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study. Kanazawa A(1), Aida M(2), Yoshida Y(2), Kaga H(1), Katahira T(1), Suzuki L(1), Tamaki S(1), Sato J(1), Goto H(1), Azuma K(1), Shimizu T(1), Takahashi T(3), Yamashiro Y(4), Watada H(1)(5)(6)(7). Author information: (1)Department of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan. (2)Food Research Department, Yakult Central Institute, Tokyo 186-8650, Japan. (3)Yakult Honsha European Research Center for Microbiology, 9052 Gent-Zwijnaarde, Belgium. (4)Probiotics Research Laboratory, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan. (5)Center for Therapeutic Innovations in Diabetes, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan. (6)Center for Identification of Diabetic Therapeutic Targets, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan. (7)Sportology Center, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan. The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (Lacticaseibacillus paracasei strain Shirota (previously Lactobacillus casei strain Shirota) and Bifidobacterium breve strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. -0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of Bifidobacterium and total lactobacilli, the relative abundances of Bifidobacterium species such as Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum, and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes. DOI: 10.3390/nu13020558 PMCID: PMC7914668 PMID: 33567701 [Indexed for MEDLINE] Conflict of interest statement: AK has received lecture fees from Sanofi, Novartis Pharmaceuticals, Daiichi Sankyo Inc., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co., and MSD, and research funds from Mitsubishi Tanabe Pharma. JS has received lecture fees from Sanofi, Ono Pharmaceutical Co., Novo Nordisk Pharma, Novartis Pharmaceuticals, Daiichi Sankyo Inc., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co., MSD, Terumo, Medtronic Japan Co., and Dainippon Sumitomo Pharma, and research funds from Sanofi. HW has received lecture fees from Boehringer Ingelheim, Sanofi, Ono Pharmaceutical Co., Novo Nordisk Pharma, Novartis Pharmaceuticals, Eli Lilly, Sanwa Kagaku Kenkyusho, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Dainippon Sumitomo Pharma, and Kowa Co., and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co., Sanofi, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwa Kagaku Kenkyusho, Terumo Corp., Eli Lilly, Mitsubishi Tanabe Pharma, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Shionogi Pharma, Dainippon Sumitomo Pharma, Kissei Pharma, and AstraZeneca. AM, YYo, and TT are employed by the Yakult Central Institute. The other authors declare no conflict of interest.

Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury.

9. Eur J Clin Nutr. 2021 Aug;75(8):1227-1236. doi: 10.1038/s41430-020-00852-8. Epub 2021 Jan 29. Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury. Li X(1)(2), Liu Y(3), Guo X(1), Ma Y(1), Zhang H(1), Liang H(4). Author information: (1)Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China. (2)Department of Clinical Nutrition, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong, 264000, China. (3)Basic Medical College, Qingdao University of Medicine, 308 Ningxia Road, Qingdao, 266071, China. (4)Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China. qdlianghui@qdu.edu.cn. BACKGROUND: The present study aims to investigate the effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury. METHODS: In a double-blind randomized controlled trial, 158 recruited alcoholic liver injury patients were randomized to three treatments for 60 days: low-dose group (LP, n = 58, 100 ml of Lactobacillus casei strain Shirota (LcS)), high-dose group (HP, n = 54, 200 ml of LcS), and positive control group (PC, n = 46, 100 ml of special drinks without active Lactobacillus casei). Another group of 20 healthy people was served as normal control group (NC). RESULTS: The serum levels of TG and LDLC in the HP group were significantly decreased by 26.56% and 23.83%, respectively than those in the PC group (P < 0.05). After supplementation of Lactobacillus casei, there was a significant increase in the amount of Lactobacillus and Bifidobacterium when compared with the PC group (P < 0.05). CONCLUSIONS: Supplementation of Lactobacillus casei can improve lipid metabolism and regulate intestinal flora disorders in patients with alcoholic liver injury. © 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature. DOI: 10.1038/s41430-020-00852-8 PMCID: PMC8352779 PMID: 33514869 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no conflict of interest.

Efficacy of probiotics on digestive disorders and acute respiratory infections: a controlled clinical trial in young Vietnamese children.

10. Eur J Clin Nutr. 2021 Mar;75(3):513-520. doi: 10.1038/s41430-020-00754-9. Epub 2020 Sep 28. Efficacy of probiotics on digestive disorders and acute respiratory infections: a controlled clinical trial in young Vietnamese children. Mai TT(1), Thi Thu P(2), Thi Hang H(3), Trang TTT(3), Yui S(4), Shigehisa A(5), Tien VT(6), Dung TV(7), Nga PB(3), Hung NT(3), Tuyen LD(3). Author information: (1)National Institute of Nutrition, 48B Tang Bat Ho Street, Hanoi, Vietnam. truongtuyetmai@dinhduong.org.vn. (2)Haiphong University of Medicine and Pharmacy, 72 A, Nguyen Binh Khiem, Ngo Quyen, Haiphong, Vietnam. (3)National Institute of Nutrition, 48B Tang Bat Ho Street, Hanoi, Vietnam. (4)Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo, 186-8650, Japan. (5)Yakult Honsha European Research Center for Microbiology ESV, Technologiepark 4, 9052, Zwijnaarde, Belgium. (6)Yakult Vietnam Co., Ltd., 195, Truong Van Bang Street, Thanh My Loi Ward District 2, Ho Chi Minh, Vietnam. (7)Hanoi Medical University, 1, Ton That Tung, Dong Da, Hanoi, Vietnam. OBJECTIVES: To evaluate the efficacy of fermented milk containing Lactobacillus casei strain Shirota (LcS) on the incidence of constipation, diarrhea, acute respiratory infections (ARI), and nutritional status of young Vietnamese children. METHODS: A controlled field trial was conducted with 1003 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n = 510) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n = 493) was not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention, and after the 4-week follow-up period. RESULTS: Probiotic drink decreased the incidence of constipation after the 12-week intervention period (12.0% vs. 32.0%, OR = 0.28 (95% CI: 0.21-0.40), p < 0.001), tended to decrease the incidence of diarrhea (4.9% vs. 7.9%, OR = 0.60 (95% CI: 0.35-1.01), p = 0.068), and prevented the occurrence of ARI (15.9% vs. 24.5%, OR = 0.58 (95% CI: 0.42-0.79), p < 0.001), when compared with the control group. In contrast, no probiotic effects were observed for the duration of diarrhea or ARI. Weight gain was higher in the probiotic group than in the control group after 4, 8, and 12-week intervention and after the 4-week follow-up period (p < 0.05). CONCLUSIONS: Daily intake of fermented milk containing LcS strongly prevented the incidence of constipation and ARI in Vietnamese children. This study also revealed the potential effects of the use of a probiotic drink on diarrhea prevention as well as nutritional status improvement. DOI: 10.1038/s41430-020-00754-9 PMCID: PMC7943424 PMID: 32981933 [Indexed for MEDLINE] Conflict of interest statement: TTM received research funding from Yakult Honsha Co., Ltd. SY and AS are current employees of Yakult Honsha Co., Ltd., and VTT is a current employee of Yakult Vietnam Co., Ltd. All other authors have nothing to disclose.